Acurx Pharmaceuticals (NASDAQ:ACXP) Posts Quarterly Earnings Results

Acurx Pharmaceuticals (NASDAQ:ACXP) announced its quarterly earnings data on Thursday. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.11), FiscalAI reports.

Acurx Pharmaceuticals Price Performance

NASDAQ:ACXP traded down $0.06 during mid-day trading on Thursday, reaching $1.48. 261,254 shares of the company’s stock traded hands, compared to its average volume of 1,311,702. Acurx Pharmaceuticals has a 12-month low of $1.33 and a 12-month high of $8.34. The firm has a market capitalization of $6.36 million, a price-to-earnings ratio of -0.37 and a beta of -2.03. The company has a 50 day moving average price of $1.53 and a 200-day moving average price of $2.22.

Institutional Investors Weigh In On Acurx Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Armistice Capital LLC purchased a new position in shares of Acurx Pharmaceuticals during the second quarter valued at approximately $551,000. Millennium Management LLC purchased a new stake in Acurx Pharmaceuticals in the fourth quarter worth $103,000. Geode Capital Management LLC purchased a new stake in Acurx Pharmaceuticals in the fourth quarter worth $31,000. Finally, Jane Street Group LLC bought a new stake in Acurx Pharmaceuticals in the fourth quarter valued at $27,000. Hedge funds and other institutional investors own 11.53% of the company’s stock.

Analyst Upgrades and Downgrades

ACXP has been the subject of a number of recent research reports. Wall Street Zen raised Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $31.00.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).